Sartorius (SRT3) Stock Overview
Provides bioprocess solutions, and lab products and services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SRT3 Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Sartorius Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €211.00 |
| 52 Week High | €292.00 |
| 52 Week Low | €166.05 |
| Beta | 1.24 |
| 1 Month Change | 2.63% |
| 3 Month Change | -1.40% |
| 1 Year Change | -12.85% |
| 3 Year Change | -44.18% |
| 5 Year Change | -35.24% |
| Change since IPO | 339.35% |
Recent News & Updates
Shareholder Returns
| SRT3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.0% | -2.4% | 0.3% |
| 1Y | -12.8% | -20.0% | 16.7% |
Return vs Industry: SRT3 exceeded the German Life Sciences industry which returned -20% over the past year.
Return vs Market: SRT3 underperformed the German Market which returned 16.7% over the past year.
Price Volatility
| SRT3 volatility | |
|---|---|
| SRT3 Average Weekly Movement | 5.4% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: SRT3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SRT3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 13,573 | Michael Grosse | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors; software apps for bioreactors and cell culture shake flasks; fermenters; cell culture media, biolayer interferometry, microbiological testing, and fluid management products; buffers; reagents; plasmids; cellcelector flexs, incubator flowboxes, nanowell arrays, and capillaries and tips; high-throughput screening by cytometry; ultrafiltration solutions; syringe, membrane, glass and quartz microfiber, clarification, syringeless, and in-line filters; and lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, and support and services; live-cell imaging and analysis software; contract manufacturing and integration; OEM membranes and devices, weigh cells, and data analytics; connectivity, and pipetting and dispensing products; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and surface plasmon resonance and process filtration products.
Sartorius Aktiengesellschaft Fundamentals Summary
| SRT3 fundamental statistics | |
|---|---|
| Market cap | €13.15b |
| Earnings (TTM) | €95.60m |
| Revenue (TTM) | €3.44b |
Is SRT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRT3 income statement (TTM) | |
|---|---|
| Revenue | €3.44b |
| Cost of Revenue | €1.89b |
| Gross Profit | €1.56b |
| Other Expenses | €1.46b |
| Earnings | €95.60m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 22, 2025
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 45.27% |
| Net Profit Margin | 2.78% |
| Debt/Equity Ratio | 115.0% |
How did SRT3 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/15 17:46 |
| End of Day Share Price | 2025/07/15 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sartorius Aktiengesellschaft is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Theresa Dick | Bankhaus Lampe KG |
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |